- The FDA has extended its review of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) marketing application of REGEN-COV (casirivimab and imdevimab) for non-hospitalized COVID-19 patients and as prophylaxis in certain individuals.
- The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use. Regeneron has submitted additional data from its completed prophylaxis trial that the FDA has accepted for review.
- The FDA has provided a new target action date of July 13, 2022, and has not requested any further studies.
- In January 2022, FDA amended the EUA to exclude its use in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment.
- Therefore, REGEN-COV is not currently authorized for use in any U.S. state.
- REGEN-COV (casirivimab and imdevimab) is a cocktail of two monoclonal antibodies explicitly designed to block the infectivity of SARS-CoV-2, using Regeneron's proprietary VelocImmune and VelociSuite technologies.
- Regeneron invented the antibody cocktail and is collaborating with Roche Holdings AG (OTC: RHHBY), primarily responsible for development and distribution outside the U.S.
- Price Action: REGN shares are trading 0.09% higher at $732.64 on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks